Skip to content
OpenCapital
Get started

PROCEPT BioRobotics Corporation PRCT Cash & Equivalents

Cash & Equivalents at other companies

TFX
TeleflexTFX
$329.55M+16.8%
Boston Scientific logo
Boston ScientificBSX
$850M+146%
Intuitive Surgical logo
Intuitive SurgicalISRG
$2.05B-21.6%
Absci Corporation logo
Absci CorporationABSI
$9.69M-84.9%
UFP Technologies logo
UFP TechnologiesUFPT
$19.98M+42.4%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$1.08B+0.5%

Other financials

Income statement

See full
Revenue$83.1M+20.2%
Gross profit$53.9M+22.2%
Operating income-$32.6M-18.8%
Net income-$31.6M-27.9%
EPS (diluted)-$0.56-24.4%

Balance sheet

See full
Total debt$78.0M-11.8%
Total equity$347.7M-10.7%
Total assets$487.1M-6.2%

Cash flow

See full
Operating cash flow-$38.1M-125%
CapEx$2.9M+58.7%
Free cash flow-$41.0M-118%

Valuation

See full
Market cap$1.19B-24.8%
Enterprise value$1.25B—
P/S3.7×—

Profitability

See full
Gross margin64%+1.3pp
Operating margin-33.9%-3.8pp
Net margin-31.8%-3.4pp
FCF margin-25%-5.7pp

Returns & leverage

See full
Return on equity-27.8%+0.2pp
Debt / equity0.2×0.0×
Current ratio6.7×-2.2×

Where this comes from

Reported directly by PROCEPT BioRobotics Corporation in its filing.

Tagged under the XBRL concept us-gaap:Cash.

The official record: PROCEPT BioRobotics Corporation’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about PROCEPT BioRobotics Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PROCEPT BioRobotics Corporation's cash & equivalents?
PROCEPT BioRobotics Corporation (PRCT) reported cash & equivalents of $12.23M in Q1 2026.
How has PROCEPT BioRobotics Corporation's cash & equivalents changed year-over-year?
PROCEPT BioRobotics Corporation's cash & equivalents decreased by 96.2% year-over-year, from $319.25M to $12.23M.
What is the long-term trend for PROCEPT BioRobotics Corporation's cash & equivalents?
Over 5 years (2020 to 2025), PROCEPT BioRobotics Corporation's cash & equivalents has grown at a -35.3% compound annual growth rate (CAGR), from $100.91M to $11.42M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.